Biotech Stocks' Dark Winter Is Over. What That Means For Investors.

The long winter for biotech stocks is over. Shares have climbed to levels not seen since late 2021, buoyed by eye-popping takeover valuations, trailblazing innovation in battling obesity and cancer, and a surprising, if uneasy, alliance with the Trump administration.

Demand For Google, Palantir Is Mere Peanuts Next To These 3 Stocks

Jobs Report Dents Fed Rate-Cut Odds; No Tariff Ruling

ETF Giant Invesco Shares What The Next Big Thing Will Be

Meta Sends These Nuclear Stocks Higher After Inking New Round Of Data Center Deals

Today's Spotlight

Navigate market volatility and stay on top of your trades with IBD Digital—try 2 months for $20.

Subscribe >

IBD Live is the best interactive broadcast for finding top stocks––try 3 months for $9.95!

Subscribe >

Listen to IBD’s podcast for new investing tips and trade ideas every week! Subscribe today.

Listen now >

Investor's Business Daily - a Dow Jones affiliate

IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC.

Sent to: dupa@niepodam.pl

Investor's Business Daily, LLC, PO Box 300, Princeton, NJ 08543-0300

Need help? Have feedback? Feel free to contact us

Terms of Use | Privacy Notice | Manage Subscriptions | Unsubscribe

ID: 7133